Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer
S-1 based treatment strategies can be cost-effective when a treatment switch is required due to HFS or CVT during fluoropyrimidine-based treatment.
Authors
- V.M.H. Coupé
- R. van Eekelen
- J.J.M. Kwakman
- C.J.A. Punt
Institutions
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106304
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00